<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Med</journal-id><journal-title>The Journal of Experimental Medicine</journal-title><issn pub-type="ppub">0022-1007</issn><issn pub-type="epub">1540-9538</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10049950</article-id><article-id pub-id-type="pmc">2192942</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Definitive Reports</subject></subj-group></article-categories><title-group><article-title>Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation? </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kerschensteiner</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Gallmeier</surname><given-names>Eike</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Behrens</surname><given-names>L&#x000fc;der</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Leal</surname><given-names>Vivian Vargas</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Misgeld</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Klinkert</surname><given-names>Wolfgang E.F.</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Kolbeck</surname><given-names>Roland</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Hoppe</surname><given-names>Edmund</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Oropeza-Wekerle</surname><given-names>Rosa-Laura</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Bartke</surname><given-names>Ilse</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x02016;</xref></contrib><contrib contrib-type="author"><name><surname>Stadelmann</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Lassmann</surname><given-names>Hans</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Wekerle</surname><given-names>Hartmut</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Hohlfeld</surname><given-names>Reinhard</given-names></name><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x0002a;</xref><xref ref-type="aff" rid="N0x1c9f450N0x1db18f8">&#x0002a;&#x0002a;</xref></contrib></contrib-group><aff id="N0x1c9f450N0x1db18f8">From the <label>&#x0002a;</label>Department of Neuroimmunology and the <label>&#x02021;</label>Department of Neurobiochemistry, Max Planck  Institute for Neurobiology, D-82152 Martinsried, Germany; the <label>&#x000a7;</label>Division of Environmental  Dermatology and Allergy, Forschungszentrum f&#x000fc;r Umwelt und Gesundheit (GSF) and Technical  University Munich, D-80802 Munich, Germany; <label>&#x02016;</label>Boehringer-Mannheim, D-82372 Penzberg,  Germany; the <label>&#x000b6;</label>Institute of Neurology, University of Vienna, A-1090 Vienna, Austria; and the  <label>&#x0002a;&#x0002a;</label>Institute for Clinical Neuroimmunology and Department of Neurology, Ludwig Maximilians  University, D-81366 Munich, Germany</aff><author-notes><fn><p>Address correspondence to Reinhard Hohlfeld, Department of Neuroimmunology, Max Planck Institute  for Neurobiology, Am Klopferspitz 18A, D-82152 Martinsried, Germany. Phone: 49-89-7095-4780; Fax:  49-89-7095-4782; E-mail: <email>hohlfeld&#x00040;neuro.mpg.de</email></p></fn></author-notes><pub-date pub-type="ppub"><day>1</day><month>3</month><year>1999</year></pub-date><volume>189</volume><issue>5</issue><fpage>865</fpage><lpage>870</lpage><history><date date-type="received"><day>24</day><month>7</month><year>1998</year></date><date date-type="rev-recd"><day>21</day><month>12</month><year>1998</year></date></history><copyright-year>1999</copyright-year><abstract><p>Brain-derived neurotrophic factor (BDNF) has potent effects on neuronal survival and plasticity  during development and after injury. In the nervous system, neurons are considered the major  cellular source of BDNF. We demonstrate here that in addition, activated human T cells, B cells,  and monocytes secrete bioactive BDNF in vitro. Notably, in T helper (Th)1- and Th2-type  CD4<sup>&#x0002b;</sup> T cell lines specific for myelin autoantigens such as myelin basic protein or myelin oligodendrocyte glycoprotein, BDNF production is increased upon antigen stimulation. The BDNF  secreted by immune cells is bioactive, as it supports neuronal survival in vitro. Using anti-BDNF  monoclonal antibody and polyclonal antiserum, BDNF immunoreactivity is demonstrable in inflammatory infiltrates in the brain of patients with acute disseminated encephalitis and multiple  sclerosis. The results raise the possibility that in the nervous system, inflammatory infiltrates have a  neuroprotective effect, which may limit the success of nonselective immunotherapies.</p></abstract><kwd-group><kwd>neurotrophic factors</kwd><kwd>multiple sclerosis</kwd><kwd>autoimmunity</kwd><kwd>immunosuppressive  therapy</kwd><kwd>neurodegeneration</kwd></kwd-group></article-meta></front><body><p>Brain-derived neurotrophic factor (BDNF) was cloned  in 1989 (<xref ref-type="bibr" rid="B1">1</xref>) as the second member of the neurotrophin  (NT) family which includes nerve growth factor (NGF)  and NT-3, -4/5, -6, and -7 (<xref ref-type="bibr" rid="B2">2</xref>). Since then, the important  role of BDNF in regulating the survival and differentiation  of various neuronal populations including sensory neurons,  cerebellar neurons, and spinal motor neurons has been  firmly established (<xref ref-type="bibr" rid="B2">2</xref>). Neurons are the major source of  BDNF in the nervous system (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). It is thought that  BDNF and NT4/5 exert their biological function via the  full-length form of <italic>trk</italic>B receptor, called gp145<italic>trk</italic>B (<xref ref-type="bibr" rid="B4">4</xref>), expression of which seems to be restricted to neuronal cell  populations (<xref ref-type="bibr" rid="B5">5</xref>).</p><p>Several studies have shown that the therapeutic application of BDNF prevents neuronal degeneration after axotomy and other forms of neuronal injury (<xref ref-type="bibr" rid="B6">6</xref>&#x02013;<xref ref-type="bibr" rid="B10">10</xref>). In addition, beneficial effects of BDNF have been reported in  animal models of neurodegenerative disease (<xref ref-type="bibr" rid="B11">11</xref>). Hence,  BDNF is now considered as a potential therapeutic agent  for human neurodegenerative disease, e.g., motor neuron  disease, although clinical trials have not yet been successful  (<xref ref-type="bibr" rid="B12">12</xref>). Considering that inflammation is a universal tissue reaction crucial for defense and repair, we asked whether the  immune cells accumulating in traumatic, degenerative, ischemic, infectious, and autoimmune lesions of the nervous  system might provide a natural imported source of BDNF.</p><sec id="MaterialsMethods" sec-type="materials|methods"><title>Materials and Methods</title><sec disp-level="3"><title>Cell Preparations.</title><p>Ag-specific CD4<sup>&#x0002b;</sup> human T cell lines were  isolated as described (<xref ref-type="bibr" rid="B13">13</xref>). PBMCs were separated into CD4<sup>&#x0002b;</sup> T  cells, CD8<sup>&#x0002b;</sup> T cells, CD19<sup>&#x0002b;</sup> B lymphocytes, and CD14<sup>&#x0002b;</sup> monocytes using immunomagnetic beads (<named-content content-type="company" xlink:href="Dynal">Dynal</named-content>). The purity of the  isolated subsets was &#x0003e;98% as determined by flow cytometry for  relevant and irrelevant subset markers (not shown).</p><p>For proliferation and BDNF production assays, 5 &#x000d7; 10<sup>5</sup> freshly  isolated CD4<sup>&#x0002b;</sup> T cells, CD8<sup>&#x0002b;</sup> T cells, and B lymphocytes were  cultured in RPMI 1640 medium (<named-content content-type="company" xlink:href="gibco">GIBCO BRL</named-content>) supplemented  with 5% FCS (<named-content content-type="company" xlink:href="gibco">GIBCO BRL</named-content>) in 96-well plates (Nunc). After a  resting period of 72 h, T lymphocytes were stimulated with 5 &#x000d7;  10<sup>4</sup> irradiated allogeneic PBMCs and PHA (10 &#x003bc;g/ml; <named-content content-type="company" xlink:href="sigma">Sigma</named-content>). B  cells were stimulated with heat-inactivated <italic>Staphylococcus aureus</italic>  Cowan strain 1 (SAC; <named-content content-type="company" xlink:href="calbiochem">Calbiochem</named-content>) at a final dilution of 1:7,500.  Monocytes were stimulated in the course of purification using  anti-CD14&#x02013;coated magnetic beads. Ag-specific T line cells (10<sup>5</sup>)  were cultured in RPMI 1640 medium supplemented with 5%  FCS plus irradiated autologous or HLA-matched PBMCs and the  relevant Ag (10&#x02013;30 &#x003bc;g/ml). Proliferation was assessed by [<sup>3</sup>H]thymidine uptake. Supernatants were removed at different time  intervals after stimulation and analyzed for BDNF protein concentration and bioactivity. BDNF production by APCs was measured in separate wells and subtracted. The cytokine profile of  CD4<sup>&#x0002b;</sup> T cell lines was assessed by intracellular flow cytometry  staining according to the manufacturer's protocol (<named-content content-type="company" xlink:href="pharmingen">PharMingen</named-content>).</p></sec><sec disp-level="3"><title>Reverse-transcription PCR Analysis of BDNF Transcription.</title><p>Total cellular RNA was extracted using two different RNA extraction systems (QIAGEN, and WAK Chemie). The RNA (0.5&#x02013;2 &#x003bc;g)  was transcribed with random hexamer primers (<named-content content-type="company" xlink:href="boehringer">Boehringer-Mannheim</named-content>) or oligo(dt) primers (<named-content content-type="company" xlink:href="gibco">GIBCO BRL</named-content>), dNTP (MBI  Fermentas), and Superscript&#x02122; Reverse Transcriptase (<named-content content-type="company" xlink:href="gibco">GIBCO  BRL</named-content>). All reactions were carried out in a total volume of 25 &#x003bc;l  containing 1 U <italic>Taq</italic> polymerase (QIAGEN), 200 &#x003bc;M of each  dNTP, cDNA, and 15 pmol of each primer for 35 or 40 PCR cycles with annealing at 60&#x000b0;C. The correct size of the bands was determined by comparison with a DNA mass standard (pUC MIX 8;  MBI Fermentas). RNA samples transcribed in the absence of  reverse transcriptase were used as negative controls to exclude  genomic contamination. All PCR products were sequenced (Medigene). The primer sequences were as follows: &#x003b2;-actin forward:  5&#x02032;-CGAGCGGGAAATCGTGCGTGA-3&#x02032; (position 622&#x02013;642);  &#x003b2;-actin reverse: 5&#x02032;-CAGCGAGGCCAGGATGGAGCC-3&#x02032; (position 1057&#x02013;1037); BDNF forward: 5&#x02032;-AGCGTGAATGGGCCCAAGGCA-3&#x02032; (position 208&#x02013;228); BDNF reverse 5&#x02032;-TGTGACCGTCCCGCCCGACA-3&#x02032; (position 570&#x02013;551).</p></sec><sec disp-level="3"><title>Quantification of BDNF Protein Secretion.</title><p>BDNF protein concentration was determined with a sensitive sandwich ELISA. In  brief, 96-well flat-bottomed plates (Immulon 4; Dynatech) were  coated with a chicken anti&#x02013;human BDNF Ab (<named-content content-type="company" xlink:href="promega">Promega</named-content>). Recombinant human BDNF (used as standard; Research Diagnostics, Inc.) and cell supernatants (all made up in RPMI, 5% FCS  plus 0.05% Tween 20 [<named-content content-type="company" xlink:href="sigma">Sigma</named-content>]) were used in serial dilutions.  Bound BDNF was detected by incubating the plates with a  mouse anti&#x02013;human BDNF Ab (Research Diagnostics, Inc.) followed by peroxidase-labeled goat anti&#x02013;mouse IgG (Dianova).  The plates were developed using a liquid substrate system  (<named-content content-type="company" xlink:href="sigma">Sigma</named-content>), and the OD was determined at 450 nm. For enhanced  detection of BDNF in biological samples, the cell supernatants  were acid-treated for 15 min before the assays. This treatment did  not change detection of the standard. Specificity of the BDNF  ELISA was established using recombinant BDNF and control  neurotrophic factors. The sensitivity of this ELISA ranges from  20 to 40 pg/ml. Quantification of BDNF was confirmed by a  second highly specific ELISA.</p></sec><sec disp-level="3"><title>Assay for BDNF Bioactivity.</title><p>Biological assays were performed  using dissociated sensory neurons prepared from nodose ganglia  of 8-d-old chick embryos (<xref ref-type="bibr" rid="B14">14</xref>). Neurons were plated in laminin/ polyornithine-coated 48-well plastic dishes. Exogenous BDNF (1  ng/ml) and immune cell supernatants were added in the presence  or absence of the anti-BDNF mAb 4.D3.3A3, which neutralizes  the biological activity of BDNF. After 24 h, the surviving neurons were counted using light microscopy. For each experiment,  duplicate wells were evaluated.</p></sec><sec disp-level="3"><title>Immunohistochemical Analysis of Brain Sections.</title><p>Immunohistochemistry was performed on formalin-fixed, frozen, and paraffin-embedded human brain tissue using a mouse IgG1 mAb against  BDNF (4.FL.1A1; 10 &#x003bc;g/ml) and a polyclonal anti-BDNF antiserum (N-20, used at 1:500 dilution; <named-content content-type="company" xlink:href="sbct">Santa Cruz Biotechnology</named-content>)  (<xref ref-type="bibr" rid="B15">15</xref>). Two actively demyelinating cases of multiple sclerosis, one  case of acute disseminated (postinfectious) leukoencephalitis, and  two controls without neurological disease were examined. Control sections were incubated without primary Ab or with control  IgG1 Ab. Serial sections were labeled for CD3 (1:300; Serotec),  CD68 (1:100; Dako), or human IgG (1:200; <named-content content-type="company" xlink:href="amersham">Amersham</named-content> <named-content content-type="company" xlink:href="pharmacia">Pharmacia Biotech</named-content>), using an avidin-biotin peroxidase method.</p></sec></sec><sec id="Results"><title>Results</title><sec disp-level="4"><title>T Cells, B Cells, and Monocytes Transcribe BDNF mRNA  and Secrete BDNF Protein.</title><p>BDNF was detected in CD4<sup>&#x0002b;</sup>  T cells, CD8<sup>&#x0002b;</sup> T cells, B cells, and monocytes (Fig. <xref ref-type="fig" rid="F1">1</xref>, a and  b). CD4<sup>&#x0002b;</sup> T cells and CD8<sup>&#x0002b;</sup> T cells were stimulated with  PHA and B cells with SAC. Monocytes were stimulated in  the course of purification with anti-CD14&#x02013;coated magnetic beads. Fig. <xref ref-type="fig" rid="F1">1</xref> b shows the BDNF concentrations in  supernatants of stimulated and nonstimulated cells after 72 h.  Constitutive BDNF production was observed in T cells  and B cells (white bars in Fig. <xref ref-type="fig" rid="F1">1</xref> b). All cell types produced enhanced levels of BDNF after stimulation (black  bars in Fig. <xref ref-type="fig" rid="F1">1</xref> b). Reverse-transcription (RT)-PCR analysis  showed BDNF transcripts in T cells, B cells, and monocytes (Fig. <xref ref-type="fig" rid="F1">1</xref> a). </p><p>BDNF was also produced by Ag-specific CD4<sup>&#x0002b;</sup> T cell  lines of different Ag specificity and cytokine profile (Table  <xref ref-type="table" rid="TI">I</xref>). Ag-induced BDNF secretion was observed both in  Th1- and in Th2-type cells (Table <xref ref-type="table" rid="TI">I</xref>). </p></sec><sec disp-level="4"><title>Immune Cell&#x02013;derived BDNF Supports Neuronal Survival In  Vitro.</title><p>Bioactivity of the BDNF produced by human immunocompetent cells was assessed by measuring the ability to  rescue cultured sensory neurons from cell death (<xref ref-type="bibr" rid="B14">14</xref>). CD4<sup>&#x0002b;</sup>  T cells, CD8<sup>&#x0002b;</sup> T cells, B cells, and monocytes were stimulated with PHA, SAC, or anti-CD14&#x02013;coated magnetic beads,  respectively. After 96 h, the supernatants were collected and  added to chicken embryonic nodose ganglia neurons to determine the neuronal survival rate (Fig. <xref ref-type="fig" rid="F2">2</xref>). Neuronal survival  was supported by externally supplied recombinant BDNF  and by supernatants of activated CD4<sup>&#x0002b;</sup> T cells, CD8<sup>&#x0002b;</sup> T cells,  B cells, and monocytes (black bars in Fig. <xref ref-type="fig" rid="F2">2</xref>). The promotion  of neuronal survival by immune cell supernatant was due to  biologically active BDNF as demonstrated by inhibition with  anti-BDNF mAb 4.D3.3A3, which blocks the biological activity of BDNF (white bars in Fig. <xref ref-type="fig" rid="F2">2</xref>). </p></sec><sec disp-level="4"><title>BDNF Is Expressed by Inflammatory Cells in Acute Disseminated Encephalitis and Multiple Sclerosis.</title><p>Strong BDNF  immunoreactivity was observed in inflammatory cells forming perivascular infiltrates in cases of disseminated (postinfectious) leukoencephalitis and multiple sclerosis (Fig. <xref ref-type="fig" rid="F3">3</xref>).  Using serial sections, BDNF<sup>&#x0002b;</sup> cells were found to correspond to infiltrating mononuclear cells (Fig. <xref ref-type="fig" rid="F3">3</xref>). In multiple  sclerosis, BDNF<sup>&#x0002b;</sup> lymphocytes and macrophages were not  restricted to the perivascular localization but were found  throughout the lesion (Fig. <xref ref-type="fig" rid="F3">3</xref> g). Lesional areas with high  numbers of macrophages actively involved in demyelination showed enhanced BDNF immunoreactivity. In  inflammatory central nervous system disease and healthy  controls, BDNF was also detected in various types of neurons, ependymal cells, and weakly in astrocytes. No immunoreactivity was observed in oligodendrocytes or ramified  microglial cells. Similar staining patterns were observed  with the monoclonal and polyclonal Abs. </p></sec></sec><sec id="Discussion"><title>Discussion</title><p>We demonstrate that human immune cells express the  neurotrophic factor BDNF both in vitro and in inflammatory brain lesions. BDNF is one of the most potent factors  supporting neuronal survival and regulating neurotransmitter release and dendritic growth (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). Several studies  have shown that the administration of BDNF protein or the  BDNF gene can rescue injured or degenerating neurons  and induce axonal outgrowth and regeneration (<xref ref-type="bibr" rid="B6">6</xref>&#x02013;<xref ref-type="bibr" rid="B10">10</xref>). Furthermore, BDNF had beneficial effects in several animal  models of neurodegenerative diseases (<xref ref-type="bibr" rid="B11">11</xref>). Difficulties in  delivering sufficient amounts of BDNF to the site of central  nervous system lesions have so far hampered the successful  application of BDNF for treatment of human diseases (<xref ref-type="bibr" rid="B12">12</xref>).</p><p>One promising strategy for the delivery of neuroprotective factors relies on retroviral transduction of neurotrophic  factors into T cell lines specific for Ag expressed in the nervous system (<xref ref-type="bibr" rid="B18">18</xref>). Our present results indicate that this experimental strategy has a natural counterpart: T cells and  other immune cells homing to degenerative, infectious, or  autoimmune lesions express a potent neurotrophic factor,  BDNF, that may help to minimize neuronal damage. Consistent with this hypothesis, it has recently been demonstrated that the implantation of activated macrophages into  experimental spinal cord lesions leads to partial functional  recovery of paraplegic rats (<xref ref-type="bibr" rid="B19">19</xref>). In addition to its neurotrophic effect, locally produced BDNF could have an  immunomodulatory function, e.g., by indirectly downregulating MHC class II expression on microglia (<xref ref-type="bibr" rid="B20">20</xref>).</p><p>NT-mediated effects on immune cells have previously  been demonstrated for nerve growth factor (<xref ref-type="bibr" rid="B21">21</xref>). Thus far,  however, we found no evidence that BDNF acts on peripheral human immune cells. This could be explained by  the fact that immune cells express only the truncated form  of the <italic>trk</italic>B BDNF receptor (our unpublished observations;  consistent with previous reports that the expression of the  full-length, signal-transducing form gp145<italic>trk</italic>B is restricted  to neuronal cells, whereas the truncated gp95<italic>trk</italic>B form is  widely expressed in nonneuronal tissues [5]). Further, we  did not detect significant effects of BDNF on the proliferation, cytokine production, or apoptosis of human lymphocytes (our unpublished data). Clearly, these negative observations by no means rule out that BDNF has a role in the  immune system, and the question of whether BDNF can  affect elements of the immune system deserves more detailed study.</p><p>BDNF production by immune cells provides a novel example of the bidirectional interaction between the nervous  system and the immune system (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>). It is noteworthy  that upon stimulation with Ag a large proportion of immune cells, including CD4<sup>&#x0002b;</sup> T cell lines specific for brain  autoantigens, produce BDNF. Thus, in some circumstances, the immune infiltrates commonly found in inflammatory, ischemic, degenerative, and traumatic lesions of  the nervous system may have a protective rather than destructive role. This could help to explain the presence of  large numbers of autoreactive T lymphocytes in the healthy  immune repertoire, a phenomenon invoked by Cohen's  concept of the &#x0201c;immune homunculus&#x0201d; (<xref ref-type="bibr" rid="B24">24</xref>).</p><p>In conclusion, our demonstration that activated T cells,  B cells, and monocytes produce BDNF in vitro and in inflammatory lesions raises the intriguing possibility that neuroinflammatory reactions have a neuroprotective (side) effect. This has obvious therapeutic implications for multiple  sclerosis and other inflammatory diseases of the nervous  system (<xref ref-type="bibr" rid="B25">25</xref>). Production of both neurotoxic and neuroprotective factors emphasizes the complex role of immune  cells in inflammatory, degenerative, and regenerative processes of the nervous system.</p></sec></body><back><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>BDNF transcription  (a) and protein secretion (b) by  stimulated (&#x0002b;) and nonstimulated  (&#x02212;) human immune cells. (a) RT-PCR analysis of BDNF transcripts. RNA was extracted with  RNAzol B (WAK Chemie) after  24 h of culture and reverse-transcribed with oligo(dt) primers.  The middle lane represents control without reverse transcriptase  (&#x02212;RT). (b) BDNF protein secretion measured in supernatants after 72 h of culture. White bars (&#x02212;), nonstimulated cells; black bars (&#x0002b;), stimulated cells (see Materials and Methods). Bars  indicate mean of duplicates; vertical lines indicate individual measurements. Lymphocyte proliferation was measured in parallel (not shown). Stimulation  indices, measured by [<sup>3</sup>H]thymidine incorporation, were &#x0003e;5 in all samples. B, B cells; M, monocytes.</p></caption><graphic xlink:href="JEM981308.f1a"/><graphic xlink:href="JEM981308.f1b"/></fig><table-wrap position="float" id="TI"><label>Table I</label><caption><p>BDNF Production by Ag-specific CD4<sup>&#x0002b;</sup> T Cell Lines </p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">TCL</th><th/><th>Antigen</th><th/><th>IFN<sup>&#x0002b;</sup></th><th/><th>IFN<sup>&#x0002b;</sup>/IL-4<sup>&#x0002b;</sup></th><th/><th>IL-4<sup>&#x0002b;</sup></th><th/><th>BDNF,&#x02212;Ag</th><th/><th>BDNF,&#x0002b;Ag</th><th/><th>SI</th></tr></thead><tbody><tr><td align="left"/><td/><td/><td/><td><italic>%</italic></td><td/><td><italic>%</italic></td><td/><td><italic>%</italic></td><td/><td><italic>pg/ml</italic></td><td/><td><italic>pg/ml</italic></td><td/><td/></tr><tr><td align="left">CABP1</td><td/><td>MBP</td><td/><td>&#x000a0;98</td><td/><td>&#x000a0;1</td><td/><td>&#x000a0;1</td><td/><td>&#x000a0;11</td><td/><td>&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;621</td><td/><td>&#x000a0;13</td></tr><tr><td align="left">HKBP</td><td/><td>MBP</td><td/><td>100</td><td/><td>&#x000a0;0</td><td/><td>&#x000a0;0</td><td/><td>239<xref ref-type="table-fn" rid="TFI-150">&#x0002a;</xref></td><td/><td>1,320<xref ref-type="table-fn" rid="TFI-150">&#x0002a;</xref></td><td/><td>ND</td></tr><tr><td align="left">TNMOG6</td><td/><td>MOG</td><td/><td>&#x000a0;99</td><td/><td>&#x000a0;1</td><td/><td>&#x000a0;0</td><td/><td>&#x000a0;&#x000a0;8<xref ref-type="table-fn" rid="TFI-150">&#x0002a;</xref></td><td/><td>&#x000a0;&#x02009;&#x02009;&#x02009;960<xref ref-type="table-fn" rid="TFI-150">&#x0002a;</xref></td><td/><td>ND</td></tr><tr><td align="left">CLBP3</td><td/><td>MBP</td><td/><td>&#x000a0;61</td><td/><td>&#x000a0;8</td><td/><td>31</td><td/><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x02009;&#x02009;&#x02009;220</td><td/><td>&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;876</td><td/><td>172</td></tr><tr><td align="left">HW&#x003b2;70</td><td/><td>rTCR</td><td/><td>&#x000a0;59</td><td/><td>12</td><td/><td>29</td><td/><td>&#x000a0;&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;0<xref ref-type="table-fn" rid="TFI-150">&#x0002a;</xref></td><td/><td>&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;370<xref ref-type="table-fn" rid="TFI-150">&#x0002a;</xref></td><td/><td>ND</td></tr><tr><td align="left">HWPPD</td><td/><td>PPD</td><td/><td>&#x000a0;24</td><td/><td>36</td><td/><td>40</td><td/><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x02009;&#x02009;&#x02009;658</td><td/><td align="left">&#x000a0;&#x000a0;&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;1,096</td><td/><td>131</td></tr><tr><td align="left">HWTT</td><td/><td>TT</td><td/><td>&#x000a0;31</td><td/><td>38</td><td/><td>31</td><td/><td align="left">&#x000a0;&#x000a0;1,364</td><td/><td align="left">&#x000a0;&#x000a0;&#x000a0;1,003</td><td/><td>&#x000a0;&#x000a0;6</td></tr><tr><td align="left">MKTT11</td><td/><td>TT</td><td/><td>&#x000a0;&#x000a0;7</td><td/><td>&#x000a0;9</td><td/><td>84</td><td/><td>&#x000a0;0</td><td/><td>&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;100</td><td/><td>&#x000a0;&#x000a0;5</td></tr><tr><td align="left">MKB6</td><td/><td>rPhl</td><td/><td>&#x000a0;&#x000a0;3</td><td/><td>20</td><td/><td>77</td><td/><td>&#x000a0;0</td><td/><td>&#x02009;&#x02009;&#x02009;&#x02009;356</td><td/><td>&#x000a0;33</td></tr><tr><td align="left">MKB7</td><td/><td>rPhl</td><td/><td>&#x000a0;&#x000a0;2</td><td/><td>14</td><td/><td>84</td><td/><td>&#x000a0;0</td><td/><td>&#x000a0;&#x02009;&#x02009;&#x02009;&#x02009;88</td><td/><td>687</td></tr><tr><td align="left">CLBP7</td><td/><td>MBP</td><td/><td>&#x000a0;&#x000a0;2</td><td/><td>&#x000a0;2</td><td/><td>96</td><td/><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x02009;&#x02009;&#x02009;482</td><td/><td align="left">&#x000a0;&#x000a0;&#x02009;&#x02009;&#x02009;&#x02009;1,154</td><td/><td>471</td></tr><tr><td align="left">CLBP14</td><td/><td>MBP</td><td/><td>&#x000a0;&#x000a0;0</td><td/><td>&#x000a0;2</td><td/><td>98</td><td/><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x02009;&#x02009;158</td><td/><td>&#x02009;&#x02009;&#x02009;&#x02009;920</td><td/><td>892</td></tr><tr><td align="left">CLBP16</td><td/><td>MBP</td><td/><td>&#x000a0;&#x000a0;2</td><td/><td>&#x000a0;4</td><td/><td>94</td><td/><td>62</td><td/><td>&#x02009;&#x02009;&#x02009;&#x02009;977</td><td/><td>393</td></tr></tbody></table><table-wrap-foot><fn><p>Columns 1 and 2 list T cell line (TCL) identification code and Ag specificity (MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; rTCR, recombinant T cell receptor &#x003b2; chain; TT, tetanus toxoid; PPD, purified protein derivate of <italic>Mycobacterium tuberculosis</italic>; rPhl, recombinant  <italic>Phleum pratense</italic>). Columns 3&#x02013;5 indicate the cytokine profile as determined by intracellular double-staining for IFN-&#x003b3; (IFN) and IL-4 and FACS<sup>&#x000ae;</sup>  analysis (percentage of stained cells). Columns 6 and 7 show BDNF concentrations as measured by ELISA in supernatants of nonstimulated (&#x02212;AG)  and Ag-stimulated (&#x0002b;AG) T cell lines after 72 h (&#x000a0;</p></fn><fn id="TFI-150"><label>&#x0002a;</label><p>after 24 h). Column 8 lists Ag-induced stimulation measured by [<sup>3</sup>H]thymidine incorporation between 48 and 72 h (SI, stimulation index).              &#x000a0;</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F2"><label>Figure 2</label><caption><p>Bioactivity of immune cell&#x02013;derived BDNF. Chicken nodose  ganglia neurons were cultured in the presence of supernatants (diluted  1:2&#x02013;1:16) of activated CD4<sup>&#x0002b;</sup> and CD8<sup>&#x0002b;</sup> T cells, B cells (B), and monocytes (M). Results are shown only for the 1:2 dilution. The neuronal cell  assays were done in the presence (white bars, &#x0002b;) or absence (black bars,  &#x02212;) of the neutralizing anti-BDNF mAb 4.D3.3A3 (4 &#x003bc;g/ml). Medium  (Med) alone served as the negative control and exogenous BDNF (1 ng/ ml) as the positive control. Bars indicate mean of duplicates; vertical lines  indicate individual measurements.</p></caption><graphic xlink:href="JEM981308.f2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Expression of BDNF  in inflammatory cells in acute disseminated (postinfectious) leukoencephalitis and multiple sclerosis. (a, c&#x02013;e) Serial sections of a  perivascular inflammatory infiltrate in postinfectious leukoencephalitis (original magnification:  &#x000d7;1,000): (a) immunolabeling of  BDNF (mAb); (c) negative control without primary Ab; (d)  CD3-labeled T cells; (e) CD68<sup>&#x0002b;</sup>  macrophages; (b) inflammatory  cells in a cryostat section from the  same patient stained with a polyclonal anti-BDNF antiserum  (original magnification: &#x000d7;500).  (f&#x02013;h) BDNF immunoreactivity in  multiple sclerosis (original magnification: &#x000d7;450): (f) in inflammatory cells forming a perivascular  infiltrate, and (g) in inflammatory  cells invading the plaque area; (h)  negative control.</p></caption><graphic xlink:href="JEM981308.f3"/></fig></sec><ack><p>The authors are grateful to M. S&#x000f6;lch for technical assistance; Drs. R. Lindert, T. Nickel, and E. Wilharm for  support; and Drs. Y.-A. Barde, D. Jenne, and H. Neumann for valuable suggestions and critical reading of  the manuscript.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leibrock</surname><given-names>J</given-names></name><name><surname>Lottspeich</surname><given-names>F</given-names></name><name><surname>Hohn</surname><given-names>A</given-names></name><name><surname>Hofer</surname><given-names>M</given-names></name><name><surname>Hengerer</surname><given-names>B</given-names></name><name><surname>Masiakowski</surname><given-names>P</given-names></name><name><surname>Thoenen</surname><given-names>H</given-names></name><name><surname>Barde</surname><given-names>Y-A</given-names></name></person-group><article-title>Molecular cloning and expression of brain-derived neurotrophic factor</article-title><source>Nature</source><year>1989</year><volume>341</volume><fpage>149</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">2779653</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewin</surname><given-names>GR</given-names></name><name><surname>Barde</surname><given-names>Y-A</given-names></name></person-group><article-title>Physiology of the neurotrophins</article-title><source>Annu Rev Neurosci</source><year>1996</year><volume>19</volume><fpage>289</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">8833445</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hofer</surname><given-names>M</given-names></name><name><surname>Pagliusi</surname><given-names>SR</given-names></name><name><surname>Hohn</surname><given-names>A</given-names></name><name><surname>Leibrock</surname><given-names>A</given-names></name><name><surname>Barde</surname><given-names>Y-A</given-names></name></person-group><article-title>Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain</article-title><source>EMBO  (Eur Mol Biol Organ) J</source><year>1990</year><volume>9</volume><fpage>2459</fpage><lpage>2464</lpage><pub-id pub-id-type="pmid">2369898</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Nanduri</surname><given-names>V</given-names></name><name><surname>Jing</surname><given-names>S</given-names></name><name><surname>Lamballe</surname><given-names>F</given-names></name><name><surname>Tapley</surname><given-names>P</given-names></name><name><surname>Bryant</surname><given-names>S</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>KR</given-names></name><name><surname>Reichardt</surname><given-names>LF</given-names></name><name><surname>Barbacid</surname><given-names>M</given-names></name></person-group><article-title>The <italic>trk</italic>B tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3</article-title><source>Cell</source><year>1991</year><volume>66</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">1649702</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lomen-Hoerth</surname><given-names>C</given-names></name><name><surname>Shooter</surname><given-names>EM</given-names></name></person-group><article-title>Widespread neurotrophin receptor expression in the immune system and other nonneuronal rat tissues</article-title><source>J Neurochem</source><year>1995</year><volume>64</volume><fpage>1780</fpage><lpage>1789</lpage><pub-id pub-id-type="pmid">7891106</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sendtner</surname><given-names>M</given-names></name><name><surname>Holtmann</surname><given-names>B</given-names></name><name><surname>Kolbeck</surname><given-names>R</given-names></name><name><surname>Thoenen</surname><given-names>H</given-names></name><name><surname>Barde</surname><given-names>Y-A</given-names></name></person-group><article-title>Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section</article-title><source>Nature</source><year>1992</year><volume>360</volume><fpage>757</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">1465147</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Q</given-names></name><name><surname>Elliott</surname><given-names>J</given-names></name><name><surname>Snider</surname><given-names>WD</given-names></name></person-group><article-title>Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death</article-title><source>Nature</source><year>1992</year><volume>360</volume><fpage>753</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">1281520</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gravel</surname><given-names>C</given-names></name><name><surname>G&#x000f6;tz</surname><given-names>R</given-names></name><name><surname>Lorrain</surname><given-names>A</given-names></name><name><surname>Sendtner</surname><given-names>M</given-names></name></person-group><article-title>Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons</article-title><source>Nat Med</source><year>1997</year><volume>3</volume><fpage>765</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">9212104</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>NR</given-names></name><name><surname>Fan</surname><given-names>D-P</given-names></name><name><surname>Giehl</surname><given-names>KM</given-names></name><name><surname>Bedard</surname><given-names>AM</given-names></name><name><surname>Wiegand</surname><given-names>SJ</given-names></name><name><surname>Tetzlaff</surname><given-names>W</given-names></name></person-group><article-title>BDNF and NT-4/5 prevent atrophy of rat rubrospinal neurons after cervical axotomy, stimulate GAP-43 and T&#x003b1;1-tubulin mRNA expression, and promote axonal regeneration</article-title><source>J Neurosci</source><year>1997</year><volume>17</volume><fpage>9583</fpage><lpage>9595</lpage><pub-id pub-id-type="pmid">9391013</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McTigue</surname><given-names>DM</given-names></name><name><surname>Horner</surname><given-names>PJ</given-names></name><name><surname>Stokes</surname><given-names>BT</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name></person-group><article-title>Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord</article-title><source>J Neurosci</source><year>1998</year><volume>18</volume><fpage>5354</fpage><lpage>5365</lpage><pub-id pub-id-type="pmid">9651218</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitsumoto</surname><given-names>H</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Klinkosz</surname><given-names>B</given-names></name><name><surname>Cedarbaum</surname><given-names>JM</given-names></name><name><surname>Wong</surname><given-names>V</given-names></name><name><surname>Lindsay</surname><given-names>RM</given-names></name></person-group><article-title>Arrest of motor neuron disease in <italic>wobbler</italic>mice cotreated with CNTF and BDNF</article-title><source>Science</source><year>1994</year><volume>265</volume><fpage>1107</fpage><lpage>1110</lpage><pub-id pub-id-type="pmid">8066451</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sagot</surname><given-names>Y</given-names></name><name><surname>Vejsada</surname><given-names>R</given-names></name><name><surname>Kato</surname><given-names>AC</given-names></name></person-group><article-title>Clinical and molecular aspects of motoneurone diseases: animal models, neurotrophic factors and Bcl-2 oncoprotein</article-title><source>Trends Pharmacol Sci</source><year>1997</year><volume>18</volume><fpage>330</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">9345852</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pette</surname><given-names>M</given-names></name><name><surname>Fujita</surname><given-names>K</given-names></name><name><surname>Wilkinson</surname><given-names>D</given-names></name><name><surname>Altmann</surname><given-names>DM</given-names></name><name><surname>Trowsdale</surname><given-names>J</given-names></name><name><surname>Giegerich</surname><given-names>G</given-names></name><name><surname>Hinkkanen</surname><given-names>A</given-names></name><name><surname>Epplen</surname><given-names>JT</given-names></name><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Wekerle</surname><given-names>H</given-names></name></person-group><article-title>Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors</article-title><source>Proc Natl Acad Sci USA</source><year>1990</year><volume>87</volume><fpage>7968</fpage><lpage>7972</lpage><pub-id pub-id-type="pmid">1700423</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;tz</surname><given-names>R</given-names></name><name><surname>Kolbeck</surname><given-names>R</given-names></name><name><surname>Lottspeich</surname><given-names>F</given-names></name><name><surname>Barde</surname><given-names>Y-A</given-names></name></person-group><article-title>Production and characterization of recombinant mouse neurotrophin-3</article-title><source>Eur J Biochem</source><year>1992</year><volume>204</volume><fpage>745</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">1541287</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vass</surname><given-names>K</given-names></name><name><surname>Berger</surname><given-names>ML</given-names></name><name><surname>Nowak</surname><given-names>TS</given-names></name><name><surname>Welch</surname><given-names>WJ</given-names></name><name><surname>Lassmann</surname><given-names>H</given-names></name></person-group><article-title>Induction of stress protein hsp70 in nerve cells after status epilepticus in the rat</article-title><source>Neurosci Lett</source><year>1989</year><volume>100</volume><fpage>259</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">2761775</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barde</surname><given-names>Y-A</given-names></name></person-group><article-title>Help from within for damaged neurons</article-title><source>Nature</source><year>1997</year><volume>385</volume><fpage>391</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">9009184</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thoenen</surname><given-names>H</given-names></name></person-group><article-title>Neurotrophins and neuronal plasticity</article-title><source>Science</source><year>1995</year><volume>270</volume><fpage>593</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">7570017</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gehrmann</surname><given-names>J</given-names></name><name><surname>Gold</surname><given-names>R</given-names></name><name><surname>Thoenen</surname><given-names>H</given-names></name><name><surname>Wekerle</surname><given-names>H</given-names></name></person-group><article-title>Gene transfer through the blood-nerve barrier: nerve growth factor engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis</article-title><source>Nat Med</source><year>1995</year><volume>1</volume><fpage>1162</fpage><lpage>1166</lpage><pub-id pub-id-type="pmid">7584988</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rapalino</surname><given-names>O</given-names></name><name><surname>Lazarov-Spiegler</surname><given-names>O</given-names></name><name><surname>Agranov</surname><given-names>E</given-names></name><name><surname>Velan</surname><given-names>GJ</given-names></name><name><surname>Yoles</surname><given-names>E</given-names></name><name><surname>Fraidakis</surname><given-names>M</given-names></name><name><surname>Solomon</surname><given-names>A</given-names></name><name><surname>Gepstein</surname><given-names>R</given-names></name><name><surname>Katz</surname><given-names>A</given-names></name><name><surname>Belkin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats</article-title><source>Nat Med</source><year>1998</year><volume>4</volume><fpage>814</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">9662373</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>H</given-names></name><name><surname>Misgeld</surname><given-names>T</given-names></name><name><surname>Matsumuro</surname><given-names>K</given-names></name><name><surname>Wekerle</surname><given-names>H</given-names></name></person-group><article-title>Neurotrophins inhibit class II inducibility of microglia: involvement of the p75 receptor</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>5779</fpage><lpage>5784</lpage><pub-id pub-id-type="pmid">9576961</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Torcia</surname><given-names>M</given-names></name><name><surname>Bracci-Laudiero</surname><given-names>L</given-names></name><name><surname>Lucibello</surname><given-names>M</given-names></name><name><surname>Nencioni</surname><given-names>L</given-names></name><name><surname>Labardi</surname><given-names>D</given-names></name><name><surname>Rubatelli</surname><given-names>A</given-names></name><name><surname>Cozzolino</surname><given-names>F</given-names></name><name><surname>Aloe</surname><given-names>L</given-names></name><name><surname>Garaci</surname><given-names>E</given-names></name></person-group><article-title>Nerve growth factor is an autocrine survival factor for memory B lymphocytes</article-title><source>Cell</source><year>1996</year><volume>85</volume><fpage>345</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">8616890</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steinman</surname><given-names>L</given-names></name></person-group><article-title>Connections between the immune system and the nervous system</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>7912</fpage><lpage>7914</lpage><pub-id pub-id-type="pmid">8367442</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>H</given-names></name><name><surname>Wekerle</surname><given-names>H</given-names></name></person-group><article-title>Neuronal control of the immune response in the central nervous system: linking brain immunity to neurodegeneration</article-title><source>J Neuropathol Exp  Neurol</source><year>1998</year><volume>58</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9600191</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>IR</given-names></name></person-group><article-title>The cognitive paradigm and the immunological homunculus</article-title><source>Immunol Today</source><year>1992</year><volume>13</volume><fpage>490</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">1463581</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hohlfeld</surname><given-names>R</given-names></name></person-group><article-title>Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives</article-title><source>Brain</source><year>1997</year><volume>120</volume><fpage>865</fpage><lpage>916</lpage><pub-id pub-id-type="pmid">9183256</pub-id></citation></ref></ref-list><fn-group><fn><p>The Institute for Clinical Neuroimmunology is supported by the Hermann und Lilly Schilling-Foundation  and Max Planck-Society. This project was further supported by the Deutsche Forschungsgemeinschaft (SFB  217, C13), Hertie-Stiftung (GHS 339/95), and European Community (BMH4-CT96-0893: Immunoregulatory aspects of T cell autoimmunity in multiple sclerosis). R.L. Oropeza-Wekerle was supported by GSF  FE-72121 and the Klinik and Poliklinik f&#x000fc;r Dermatologie and Allergologie, Technical University of Munich. This study is part of the M.D. theses of M. Kerschensteiner and E. Gallmeier.</p></fn></fn-group></back></article>


